U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07024277) titled 'Study of ZG006 in Participants With Neuroendocrine Prostate Cancer' on June 09.
Brief Summary: This is a multicenter, open-label Phase II study, aimed at exploring the preliminary efficacy and safety of ZG006 in patients with advanced metastatic NEPC who have previously failed standard treatment.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Neuroendocrine Prostate Cancer
Intervention:
BIOLOGICAL: ZG006
ZG006 will be administered as an intravenous (IV) infusion.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Published by HT Digital Content Services with permiss...